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Infections and sepsis represent a growing global burden. There is a widespread clinical need for a rapid,
high-throughput and sensitive technique for the diagnosis of infections and detection of invading
pathogens and the presence of sepsis. Current diagnostic methods primarily consist of laboratory-based
haematology, biochemistry and microbiology that are time consuming, labour- and resource-intensive,
and prone to both false positive and false negative results. Current methods are insufficient for the
increasing demands on healthcare systems, causing delays in diagnosis and initiation of treatment, due
to the intrinsic time delay in sample preparation, measurement, and analysis. Vibrational spectroscopic
techniques can overcome these limitations by providing a rapid, label-free and low-cost method for
blood analysis, with limited sample preparation required, potentially revolutionising clinical diagnostics by
producing actionable results that enable early diagnosis, leading to improved patient outcomes. This
review will discuss the challenges associated with the diagnosis of infections and sepsis, primarily within
the UK healthcare system. We will consider the clinical potential of spectroscopic point-of-care
technologies to enable blood analysis in the primary-care setting.1. Introduction
1.1 Infections
An infection can be dened as the “pathologic process caused
by the invasion of normally sterile tissue or uid or body cavity
by pathogenic or potentially pathogenic microorganisms”.1
Infection can result from bacterial, viral, yeast or fungal
microbial invasion. Despite advances in the delivery of more
effective and efficient healthcare, infections are becoming
increasingly common.2 In part this is due to more compre-
hensive reporting, but also to factors such as aging populations,
existing co-morbidities and increasing use of invasive proce-
dures.3 In the last 40 years the mortality rate due to infectious
diseases in the UK has seen an overall decline due toedical Engineering, Wolfson Centre, 106
d Chemistry, Technology and Innovation
UK. E-mail: matthew.baker@strath.ac.uk;
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Greater Glasgow and Clyde, 1345 Govan
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f Chemistry 2021improvements in healthcare and lifestyle,4 but still constitute
7% of recorded deaths.5
Infections are particularly common in intensive care units
(ICUs), immunosuppressed, and in elderly and critically ill
patients. There are different factors contribution to infection
susceptibility, such as age or impaired immune system due to
disease or drugs. Table 1 lists the most signicant factors that
increase the risk of signicant infection. Hospital acquired
infections (HAIs) are the most common adverse effect associ-
ated with the delivery of healthcare in developed countries,
primarily due to the proximity of unwell and high-risk patients
along with the likelihood of patients undergoing invasive
procedures. Over 300 000 patients annually (6%) are affected
with HAIs in England, at a costs of around £1 billion to the
NHS:6,7 predominately respiratory tract (22.8%), urinary tract
(17.2%), surgical site (15.7%) infections and clinical sepsis
(10.5%).8 The incidence of HAIs is 3.7–11.6% in developed
countries,9 rising to 14–31% in developing countries.10
Overall, in the last 40 years, there has been a general trend in
the increase of the life expectancies of both males (8.3 years)
and females (6.1 years) in the UK.4 However, a longer life
expectancy does not necessarily reect a healthier population.
Pre-existing co-morbidities are particularly common in the
elderly, for example, with 64.9% of people over the age of 65 in
Scotland having two or more chronic medical conditions.11 Co-
morbidities alone are not sufficient to increase susceptibility to
infection but may involve other factors such as recurrentAnal. Methods, 2021, 13, 157–168 | 157
Table 1 Factors increasing risk of patients developing infection or sepsis
Risk Factors increasing risk of infection
Immunocompromised patients  Underlying malignancy – neutropenia, tumour obstruction, curative
treatment, nutritional factors and use of invasive devices93
 Anticancer or immunomodulatory therapies suppress the normal
function of the immune system. Patient may be neutropenic93
 The bonemarrow is unable tomaintain production of white blood cells
at required rate21
Under 1 year of age  Premature94




 Immune system still developing21
Over 75 years of age Extracted from ref. 12:
 Limited mobility causing skin breakdown and ulcers
 Loss of coordination resulting in injury and falls
 Poor urinary bladder emptying
 Increased incidence of obstructions (gallstones, and urinary tract
stones)
 Age-related diseases including dementia
 Immunosenescence – poor response to vaccinations and increasing
incidence of infections
Surgery/invasive procedure in past 6 weeks  Prolonged operation98
 Surgical site99
 Surgery complexity100
 Patient factors – existing comorbidities, age, frailty98
 Complications encountered in surgery100
Pregnancy  Immune alterations with advancing pregnancy101
 Pathophysiological changes (for example decrease in respiratory
volume and increase in heart rate)102
 Aerobic and anaerobic bacteria in vagina and endocervical canal102
Breach of skin integrity (cuts, burns, blisters for example)  Skin is the body's external rst line of defence
 When the skin is broken, microorganisms can enter the wound and
cause an infection103
Intravenous drug users (IDU)  Sharing of needles and syringes104
 Unsterile injection practices104
 Contaminated drugs can cause spore-forming infections105
 Existing diagnosis of HIV, hepatitis C, hepatitis B106
Invasive devices (urinary catheter, PICC line for example)  Contamination of device during insertion107
 Inefficient cleaning and sterilisation of insertion site108
 Unnatural opening into the body can allow bacteria and fungi to
enter108
 Lack of frequency of line replacement107






























































































View Article Onlinehospitalizations, medications and the immune system senes-
cence.12 These factors, together with inactive lifestyle, muscle
loss and changes in bodily function, contribute to increased risk
of clinically-signicant infection.13
In many cases, an infection may be obvious by a physical
examination, such as high fever or altered mental state14 but
some patients may show minimal clinical symptoms. For
example, if a patient is already immunosuppressed, then they
may not develop a fever despite an infection being present.15
Certain medications, such as beta-blockers, can also mask
symptoms and cause difficulty in diagnosing infection,16
resulting in later-stage detection with corresponding higher
morbidity and mortality.
The treatment of infection centres around source control
and effective implementation of therapy (e.g. antibiotic, anti-
viral). The application of microorganisms for the treatment of158 | Anal. Methods, 2021, 13, 157–168microbial infections has been dated back to ancient Egypt,
Greece and China, but the pivotal transition into modern era
antibiotics was the discovery of penicillin by Sir Alexander
Fleming in 1928.17 Unfortunately, over-use of antibiotics has led
to the promotion of antibiotic resistant bacteria. This was rst
reported in the early 1950s and now is reported for almost all
antibiotics, causing infections to become more challenging to
control and eradicate.18 The World Health Organization has
classed antibiotic resistance as a “global health threat” that is
responsible for 700 000 deaths globally each year. Antibiotic
resistance will always occur in new drugs, but the timelines for
this is unpredictable.
1.2 Sepsis
In many cases, an infection will not be life threatening and can
be effectively eradicated by a course of appropriate treatment.This journal is © The Royal Society of Chemistry 2021






























































































View Article OnlineHowever, in some cases it can lead to a cascade of pro- and anti-
inammatory responses that may cause organ dysfunction,
permanent damage or even death if not controlled and treated
promptly. Sepsis is then dened as “a life-threatening organ
dysfunction due to a dysregulated host response to an
infection”.19
Sepsis may follow infection for example due to injury, burn
or surgery. Seventy percent of cases result from bacterial origins
compared to 20% from viral and 10% from fungal infection.20
However, not all cases of an infection will result in sepsis. The
determination of the cause of sepsis (i.e. bacterial, viral, or
fungal) is useful to ensure appropriate and effective treatment.
The National Condential Enquiry into Patient Outcome and
Death (NCEPOD) found that approximately 80% of sepsis cases
in the UK were due to community-acquired infection.21 At the
onset of sepsis, pro-inammatory pathways are dominant, with
anti-inammatory responses at later stages. Patient with sepsis
will typically become immunosuppressed early, due to mal-
functioning innate or adaptive immune systems.22 The patho-
genesis of sepsis at the molecular, cellular and organ levels has
been reviewed in detail.20
Sepsis, severe sepsis and septic shock represent increasingly
severe systemic inammatory responses to an infection.20 Septic
shock is the most likely to be fatal as a result of extensive
circulatory and metabolic abnormalities.19 There has been
debate over the connection of Systemic Inammatory Response
Syndrome (SIRS), sepsis and septic shock as a continuum of
increasing severity, rather than classing them as individual
conditions, since not all SIRS patients will subsequently develop
septic shock.23 Sepsis and SIRS can both lead to organ failure
but by different physiological processes.
It is well documented that early and accurate identication
of sepsis is crucial to successful treatment and outcome.24–26
However, there is currently no gold standard diagnostic process
for septic patients, so that identication relies on clinical
suspicion together with physiological and laboratory tests.
When sepsis is suspected, initial screening measurements of
temperature, heart rate and respiratory rate are performed,
followed by blood glucose, urine output, blood pressure, oxygen
saturations and serum lactate measurements. Pathogenic blood
cultures are also performed, followed by further investigations
as required, such as imaging, urinalysis, or urine culture.
Denite diagnosis of sepsis requires conrming the presence of
an underlying infection through positive blood culture. Diag-
nosis of sepsis is made more challenging by overlap of clinical
symptoms with other non-infectious conditions that share
a systemic inammatory response, such as pancreatitis, tissue
ischemia, trauma and drug reactions.20 Sepsis is, therefore,
commonly under- or over-diagnosed and delayed initiation of
treatment can have devastating impact, both on survival and on
post-sepsis complications that occur in some 40% of cases.21
Low-income countries bear the greatest burden with cases of
sepsis, primarily due to deprived living conditions with poor
preventative healthcare, insufficient sanitation, malnutrition
and a higher incidence of tropical and viral diseases.27 These
countries represent around 74% of global deaths relating to
sepsis per year.28 Factors such as lack of awareness of sepsis,This journal is © The Royal Society of Chemistry 2021limited access to treatment29 and concomitant healthcare, and
the prevalence of counterfeit medications30 all contribute to
poor patient outcomes. On an annual basis, there are approxi-
mately 30 million cases of sepsis reported globally, increasing
by 9% per year.31,32 Over 6 million cases will result in death,
although the real number is expected to be much higher,
because of lack of information from low-to-middle income
countries and inconsistencies in listing sepsis as the cause of
death.33
In the UK, there are approximately 200 000 cases of sepsis
annually, resulting in over 46 000 deaths,21 representing 5–7%
of all deaths.34 The incidence is increasing by 11.5% per year,21
and it is 6 times more expensive to treat septic than non-septic
patients,33 so sepsis represents a growing nancial burden in
both direct and indirect costs, the former being estimated as
£2B per year.21 Implementation of more effective diagnostic
tools allowing sepsis to be identied within one hour of patient
presentation is estimated to save the NHS upwards of £170M
per year in care and treatment.31.3 Current diagnostic pathway
As discussed above, early identication of sepsis is critical to
successful outcome. The management of sepsis relies on the
early identication of the condition, with prompt control and
eradication of the infection. The typical diagnostic pathway for
infection and sepsis is illustrated in Fig. 1.
Microbiology testing is central to the diagnosis of infection
and sepsis, enabling optimised targeted therapy. Since sepsis
always arises from an infection, the only way to positively
diagnose sepsis is by identifying the pathogen using blood
cultures. However, these have several limitations: high volume
of blood required (20–30 mL),35 time for pathogen detection (2–
3 d) and identication (5–7 d),36 and antibiotic susceptibility
testing.37 Furthermore, only 6–15% of cultures from patients
with a suspected infection will yield a positive result,38 due to
low circulating microorganisms and the intermittent nature of
blood stream infections.39,40 False positive results,40 culture
contamination41 and low blood culture volumes42 are also
problematic. Hence, blood cultures are only taken in about 50%
of cases of suspected sepsis.38
Efforts are being made to develop rapid diagnostic tools
particularly for pathogen identication and determination of
antibiotic resistance to allow for a more targeted approach. The
polymerase chain reaction (PCR) technique has been the most
prominent development in the quest for rapid pathogen capture
and detection systems, by amplifying the pathogen signal. They
are typically less time consuming than blood culture/colony
counting, typically taking 5–24 h, depending on the specic
method used.43 Optical biosensors,44 bioluminescent sensors,45
and ow cytometry46 have all been investigated for pathogen
detection but pathogen amplication is still required in almost
all cases. These techniques will be discussed in more detail
below.
The use of SIRS criteria for diagnosing sepsis is not fully
endorsed and it has been well documented that these criteria
are not specic to an infectious cause, with up to 90% of acutelyAnal. Methods, 2021, 13, 157–168 | 159
Fig. 1 Typical clinical pathway to the diagnosis of infection or sepsis. Adapted from ref. 15.






























































































View Article Onlineill patients fullling the criteria even in the absence of an
infection, for example following recent trauma or surgery.47,48
This can lead to clinicians treating SIRS-positive and septic
patients equally. However, the criteria are still relevant in initial
patient assessment and identifying if the patient is likely to have
an underlying infection and have laid the groundwork for more
comprehensive sepsis assessment tools to be used for risk
stratication in the initial assessment period. Details of these
screening tools and their respective advantages and disadvan-
tages are summarized in Table 2.
Patients identied as at risk for sepsis are then assessed to
identify a possible infection if this is suspected. Pneumonia is
the cause of some 50% of cases of sepsis, followed by urinary
tract infections (20%) and abdominal (15%) infections.21 To
diagnose sepsis, one or more dysfunctional organs must be
identied. The SOFA scoring system is currently the most
appropriate method for identifying and quantifying organ
dysfunction but requires two sequential scores, the rst serving
as baseline, around 24 hours apart.49 Calculation of the SOFA
score is a relatively time-consuming process, which is unreal-
istic in busy wards or emergency departments.21 In this case,
red-ag sepsis criteria are used to suggest the degree of organ
dysfunction (i.e. high heart rate, low blood pressure and lacta-
temia). However, this is not a formal diagnostic method and the
presence of two or more red ags can only suggest that the
patient is very likely to have sepsis. Comprehensive guidelines
to diagnose and treat sepsis have been published.21
Over 170 biomarkers have been studied for their potential to
identify and diagnose infections and sepsis at earlier stages.50
However, no biomarker exists that is specic only to sepsis.
Typically, they are indicators of inammation. As sepsis is a very
complex condition with many inammatory mediators and
pathophysiological mechanisms, the time at which a specic
biomarker would be diagnostically useful varies, which is
a challenge in assessing biomarkers for their diagnostic and
prognostic utility. The general census is that current biomarker
quantication is more useful in ruling out rather than con-
rming infection. Nevertheless, the development of a multi-
panel approach for biomarker quantication is appealing, as
a more thorough diagnostic tool with potential applications in
antibiotic stewardship. Table 3 illustrates key sepsis biomarkers
investigated for diagnostic and prognostic capabilities, together
with their advantages and limitations.
Time is a critical factor in the diagnosis and management of
sepsis, with every hour of treatment delay increasing the risk of
death by about 8%.26 Despite ongoing improvements in patient
management, there is high variability in the treatment of sepsis.
There is a general agreement that treatment should be started160 | Anal. Methods, 2021, 13, 157–168as soon as possible aer sepsis is suspected24,51 but in most
cases it is necessary to initiate treatment before the pathogen is
identied. Thus, in bacterial sepsis, the patient is initially
treated with broad-spectrum antibiotics before the results from
blood cultures are available to optimise the choice and duration
of the antibiotic therapy. Broad-spectrum antibiotics are not
always sufficient, due to increasing antimicrobial resistance of
many pathogens. However, the use of targeted, narrow-
spectrum antibiotics is only made possible by rapid identica-
tion and/or classication of the pathogen.
Treatment of sepsis typically includes uid management,
antimicrobial therapy, respiratory support, and vasoactive
drugs. The so-called sepsis 6 protocol to control infection and
restore normal function, including oxygen delivery, is recom-
mended within 1 h of suspicion of sepsis and reduces the
overall mortality by 46.6%.25 However, a review in 2015 found
that only 63% of septic patients received antimicrobials therapy
in the rst hour following diagnosis and the delay led to
negative outcomes for 44% of these patients.52
There is currently no well-dened protocol for pre-hospital
emergency care of sepsis of sepsis which averages 45 min,
whereby patients are transported to hospital by emergency
services.53 Hence, there is an unmet need for a portable, point-
of-care device to help inform emergency personnel. In the UK,
approximately 50% of patients who present to hospital emer-
gency departments with sepsis arrived by ambulance53 and
typically have more advanced sepsis and higher risk of death.
Screening tools and point-of-care tests are needed to stratify
patients and facilitate delivery of effective care.
Current diagnostic procedures for sepsis are insufficient and
cause delays in diagnosis and treatment of critically-ill
patients.54,55 New diagnostic devices are needed that t with
healthcare workows by providing a means for earlier diagnosis.2. Vibrational spectroscopy for
infection and sepsis detection
Vibrational spectroscopy comprises the complementary tech-
niques of infrared (IR) and Raman spectroscopy, using light to
probe intramolecular vibrations and rotations of a sample such
as a biospecimen. The vibrational frequencies of specic
molecules are unique, allowing molecular “ngerprinting” of
the biomolecular composition of the sample allowing a means
to deduce its chemical and structural components. This repre-
sents an opportunity for non-invasive medical diagnostics. Such
measurements, supported by computational analysis, should
allow point-of-care devices to be used by clinical personnel with
minimal training and expertise.This journal is © The Royal Society of Chemistry 2021
Table 2 Current protocols and diagnostic criteria used to diagnose infections and sepsis
Diagnosis protocol Criteria Advantages Limitations
SIRS criteria  Temperature 3 Still relevant for identifying an
infectious source
7 Poor specicity – 90% of ICU
patients and 50% of general ward
patients full criteria48,109
 Pulse rate 3 Can be used to dene
“uncomplicated sepsis” which is
without evidence of organ
dysfunction21
7 Sensitivity of 81% and specicity
of 41% for predicting mortality in
ED patients with infections110
 Respiratory rate
 White blood cell count
 Blood glucose
 New confusion
Sepsis-3  Persisting hypotension 3 Accurate at identifying very high-
risk. Patients who have a higher
mortality risk
7 Requires the presence of organ
dysfunction to diagnose sepsis
 Elevated serum lactate 3 Identies organ failure 7 Fails to identify patients with
serious infections before organ
dysfunction is established111




Organ systems analysed: 3 Accurately identies organ
dysfunction
7 Requires two scores minimum –
on admission and at each 24 hour
period that follows
 Respiratory 3 Assesses each of the 6 organ
systems to identify organ
dysfunction
7 Very time consuming
 Cardiovascular 3 Increase in SOFA score by 2 or
more is indicator of in hospital
mortality. Sensitivity 76%,
specicity 70% (ref. 112)
7 Fails to identify sepsis at early
stages
 Renal 7 Not used outside of the ICU
 Neurological 7 Requires laboratory values which
may not be readily available Hepatic
 Haematological
Quick-SOFA (q-SOFA)  Respiratory rate 3 Used to prompt clinicians to
“think sepsis”
7 Typically identies high risk
patients too late
 Systolic blood pressure 3 Simple and quick 7 Sensitivity of 21% for predicting
in-hospital mortality on admission
into ED113
 Altered mental state 3 Specicity of 96% for predicting
in-hospital mortality on admission
into ED113
National Early Warning Score
(NEWS)
 Respiratory rate 3 Useful in ruling out sepsis 7 Low positive predictive value
(35.4%) for detecting clinical
deterioration115
 Oxygen saturation 3 Easy to use without increasing
workload
7 Brain function depends solely on
AVPU and does not discriminate




 Body temperature 3 Does not require blood test
results
 Systolic blood pressure 3 Accurate of 77% for predicting in-
house mortality114 Heart rate
 Supplemental oxygen
 AVPU score
Simplied-MISSED  Age $65 years 3 Very simple and easy to calculate 7 Relatively new system that
requires further multi-centre
validation
 Serum albumin 3 Complements already established
sepsis criteria
7 Serum albumin and INR can be
affected by the impaired synthetic





 Age $65 years 3 Easy to calculate in a busy ED 7 Sensitivity of 38% for predicting
in-hospital mortality on arrival to
ED113
 Altered mental state 3 Embraces current denition of
septic shock
7 Can only be calculated once
sepsis-6 have been completed and
blood test results are available119
 Systolic blood pressure 3 Specicity of 89% for predicting
in-hospital mortality on admission
into ED113




 International normalised ratio
 Refractory hypotension
This journal is © The Royal Society of Chemistry 2021 Anal. Methods, 2021, 13, 157–168 | 161































































































Table 3 Key biomarkers assessed for diagnosing infections and sepsis
Biomarker Suitability Advantages Limitations Current applications
C-Reactive Protein (CRP) Synthesised in the liver in





treatment duration by 1.45
days (ref. 120)




inammation. 5 mL of blood
taken in gold top tube
3 Useful in predicting
mortality risk121
7 Elevated levels in burns,
trauma, surgery and non-
infectious conditions
3 CRP levels typically double
every 8 hours aer
endotoxin challenge122
7 Marker of inammation
rather than infection
Lactate Reects the balance between
lactate production and
clearance
3 Levels >4 mmol L1
indicate a relative risk of
mortality of 40% (ref. 124)
7 Not specic to sepsis Normally assayed in blood
gas analyser machines. 2 mL
of blood is taken in
a uoride-oxalate tube3 Useful in quantifying the
level of organ failure
7 Lactate levels can be high
due to malignancy, liver
disease, mitochondrial
disorder126
3 Sensitivity of 82.9% and
specicity of 83.4% for
predicting sepsis125
Procalcitonin (PCT) Produced in the thyroid cells
and then converted to
calcitonin. Very low levels in
healthy patients. Released
within 3–4 hours aer
inammatory stimulus123
3 Bacterial endotoxins are
a key stimulus of the
synthesis of PCT and can be
used as an indicator for
bacterial infections122




Not routinely available in
NHS currently. 3.5 mL of
blood taken in rust top gel
tube3 Sensitivity of 72.7% and
specicity of 81.7% for
predicting sepsis67
7 Assays are expensive and
are prone to false results
3 Demonstrated to reduce
the duration of antibiotics
by 2.7 days127
7 Variation in PCT assays
and predictive cut-off points
cause difficulties in
interpretation of results128
Neutrophil (count) Constitute 50–70% of all
circulating white blood cells.
They are the rst cells to
respond to an infection
3 Already used in the
denition of sepsis and
diagnostic criteria
7 62.9% sensitivity and
62.8% specicity for
predicting sepsis125




laboratory. Up to 5 mL of




an increase in neutrophil
and white blood cell count
7 Neutrophil count may be
very high or very low if the
patient has an infection
Immature Granulocyte (IG)
(count)
Number of white blood cells
with granules in their
cytoplasm and two or more




3 Provides information on
bone marrow activity
7 Sensitivity of 60% and





microscopy counts can be
used to calculate IG count.
Up to 5 mL of blood
collected in lavender top
tube (EDTA)
3Healthy individuals do not
have IG present in
peripheral blood




patients with a sensitivity of
89.2% and specicity of
76.4% (ref. 129)
Calprotectin Released upon neutrophil
activation. Constitutes




within hours aer bacterial
or endotoxin challenge131
7 Specicity of 56% for
discriminating between
sepsis and non-sepsis131
Serum calprotectin is not
currently routinely
measured in the NHS. Faecal





3 Sensitivity of 81% for
discriminating between
sepsis and non-sepsis131
7 Low specicity (46%) for
predicting 30 day
mortality131
3 High predictor of 30 day
mortality (80%
sensitivity)131






























































































View Article OnlineIn the diagnosis of infections, it is critical to identify the
specic microbe species (bacterial, fungal, or viral) to inform
the choice of treatment. Emerging technologies for this162 | Anal. Methods, 2021, 13, 157–168application include the use of PCR (polymerase chain reaction
to amplify the measurement signal by replicating the genetic
material in the sample), ow cytometry (detects and measuresThis journal is © The Royal Society of Chemistry 2021






























































































View Article Onlinephysical and chemical characteristics of cells), optical biosen-
sors (detection of optical signals that are proportionate to
concentration of analyte under investigation) and biolumines-
cent sensors (detection of light produced following chemical
reaction with biological material). Flow cytometry and
biosensor techniques typically involve a pathogen amplication
step prior to analysis. A detailed critical review of these tech-
niques for pathogen detection has been published by Raja-
paksha et al.43 Assay techniques (such as molecular based assays
or PCR-assays) have been the most studied for rapid identi-
cation of microbes, with high specicity (95%) but are labour
intensive, slow (up to 16 h) and expensive43,56 and also require
trained technical personnel.57 Flow cytometry is quantitative
and yield high sensitivity in <1 h.43 Its limitations are the need
for complex sample preparation, high equipment costs and the
need for expert operators.43,46 Optical biosensors and biolumi-
nescent sensors allow rapid, high-throughput pathogen detec-
tion and quantication of but have poor detection limits and
low sensitivity.44 Mass spectrometry has also been investigated
for rapid (<1 h) microbial identication, with low detection
limits (16 colony forming units (CFU) per mL).58–60 However, it
has limited ability to differentiate bacterial species61 and
requires extensive sample preparation compared to other
techniques.62
In principle, vibrational spectroscopies can overcome
various of these limitations, by providing a label-free analytical
method with simple sample preparation, low sample volumes
(typically mL) and the ability to obtain a molecular ngerprint
of the full sample. A comparison of the analytical steps required
for the current gold-standard technique of blood culture, the
above emerging assay techniques, and the proposed vibrational
spectroscopic techniques is presented in Table 4. Although
Table 4 shows the case for bacteria only, all techniques are
applicable to other pathogens including viruses, yeast, and
fungi.63–65 It should be noted that drying of the sample is
required for IR spectroscopy66 but is not necessary in Raman
spectroscopy. However, some reduction of the biouid water
content increases the microbe concentration and, hence, the
signal strength.67Table 4 Comparison of techniques for detection of pathogenic bacteri
Analysis step Blood cultures Assay tech
Preparation time <15 minutes (ref. 35) <1 hour (r
Volume of blood 20–30 mL per set (ref. 132) <5 mL (re
Culture time 2–7 days (ref. 35, 40 and 134) 24 hours
Drying time N/A N/A
Analysis timea <2 hoursb (ref. 35) 4–16 hour
Positive predictive value <55% for 1 culture, <98% for 2
(ref. 140)
30–57% (r
a Analysis time following blood culture. b Analysis time for identication
culture result. Additional time (24–48 h) is required to determine antibio
This journal is © The Royal Society of Chemistry 2021Signicant early research in the application of vibrational
spectroscopy to infection diagnosis was carried out by Nau-
mann and colleagues, who demonstrated such techniques to be
powerful analytical tools for the identication and character-
isation of microbial cells by the determination of spectral
characteristics from the microbes and the characteristic
absorptions of the cellular proteins of the bacteria.68,69 However,
this use of Fourier Transform Infrared (FTIR) spectroscopy for
whole-cell bacterial samples is confounded by the effect on the
acquired spectra of the culture conditions (medium, tempera-
ture and time).70
Much of the work on identifying pathogenic bacterial strains
has been accomplished by Raman spectroscopy,71,72 including
surface-enhanced Raman spectroscopy (SERS) using gold or
silver nanoparticles to amplify the otherwise weak Raman
signal. Numerous studies have shown the ability SERS to
identify and differentiate invading pathogens73 and quantify
live and dead bacteria populations.74 FTIR microspectroscopy
has demonstrated to detect and identify bacterial and yeast
microcolonies75 with classication accuracies upwards of
80%.76 More recently, FTIR spectroscopy has been reported to
identify and classify different microbial strains77 and also
identify Gram-negative bacterial species responsible for
hospital outbreaks within 3 h, using second derivative ampli-
cation clustering methods whereby microbials are classied
into distinctive groups following amplication of the differ-
ences between isolates.78 Additionally, FTIR has shown utility in
distinguishing between bacteria, fungus and viruses
microorganisms.64,79
In the diagnosis of sepsis, both the invading pathogens and
host-response biomarker concentrations are diagnostically
important to determine treatment options. Potential
biomarkers are listed in Table 3. The identication of sepsis
using vibrational spectroscopy can be achieved by detecting the
optical signatures of both the pathogens and the host
biomarkers. To date, a very limited number of studies have
considered the application of vibrational spectroscopic tech-
niques to diagnose sepsis. Raman spectroscopy has been used
to distinguish between non-infectious SIRS and sepsis usinga in clinical analysis
niques IR spectroscopy Raman spectroscopy
ef. 40) 15–25 minutes
(ref. 77 and 78)
<20 minutes (ref. 72)
f. 40) 1–5 mL (ref. 77) 1–10 mL (ref. 72 and 133)
(ref. 45) 6–24 hours
(ref. 77 and 135)
6–24 hours
(ref. 72, 73 and 133)
<30 minutes
(ref. 78 and 135)
0–60 minutes
(ref. 73 and 133)
s (ref. 40) <20 minutes
(ref. 136 and 137)
<30 minutes
(ref. 138 and 139)
ef. 56, 141 and 142) <97% (ref. 136) <97% (ref. 71)
of microorganisms by gram staining following alert of positive blood
tic susceptibility.
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View Article Onlineblood plasma samples, with a prediction accuracy of 80%.80
FTIR micro-spectroscopy has allowed the analysis of sepsis
progression in mouse models.81 Spectral changes in saliva were
observed between control and septic neonatal patients using
FTIR.82 However, vibrational spectroscopic techniques are still
currently limited by the requirement of culturing due to the low
concentrations of circulating microbes within biouids.
It has also been shown that detection of biomarkers can aid
in the identication of infections and sepsis before clinical
symptoms present.83 This would be of particular benet in the
intensive-care setting (ICUs), where patients are at a high-risk of
developing infections and resulting sepsis. FTIR spectroscopy
has been investigated to quantify glucose and lactate in whole
blood and blood serum samples.84,85 Attenuated Total
Reectance-Fourier Transform Infrared (ATR-FTIR) spectros-
copy has been shown to be useful in quantifying protein
concentrations within blood serum samples.86 There is an
extensive literature on the spectral analysis of biomarkers to aid
in the diagnosis of various types of cancer, but there a lack of
studies on infection biomarkers, such as C-Reactive Protein
(CRP) and procalcitonin (PCT), that would be useful in diag-
nosing infections and sepsis.50
A primary requirement for vibrational spectroscopy-based
devices is that they generate rapid, clinically actionable results
with high sensitivity and specicity. This requires detection
across a wide range of pathogen concentration, say 1–100 000
CFU mL1.40 Appropriate device design is crucial for successful
translation of new medical devices. In a generic sense, visual-
isation of results, necessary level of training, expertise required,
andmaintenance requirements must be appropriate for the end
user. Furthermore, the device must be suitable for its environ-
ment of use with regards to its accessibility, physical footprint
and the necessary continual costs for device use and upkeep.
Translation of vibrational spectroscopic techniques to the
routine clinical environment remains elusive, despite the large
number of studies demonstrating the performance and capa-
bilities of such techniques for other clinical applications.87,88
However, signicant modication of these technologies are
required for high-throughput, streamlined and user-friendly
use in the infection/sepsis setting89 and the methods and
devices will require extensive multicentre trials validate the
measurements and analyses. The general challenges in clinical
translation of infrared and Raman spectroscopy have been
reviewed elsewhere.66,89
As mentioned above, vibrational spectroscopy techniques
are currently still limited by the requirement of culturing before
spectral acquisition and analysis, due to the typically very low
concentrations of microbes within liquid bio-samples such as
blood (1–10 CFUmL1).39 Efforts are being made to eliminate or
reduce this requirement for the clinical environment.72
Grey areas remain in the diagnosis of sepsis, as opposed to
diagnosis of infection: in the denite presence or absence of the
condition15 and a complete diagnostic platform will require
integration of multiple diagnostic criteria, along with clinician
expertise. Vibrational spectroscopy has the potential to
contribute signicantly to the overall diagnostic process by
providing high-throughput, label-free, non-destructive and low164 | Anal. Methods, 2021, 13, 157–168cost detection of pathogenic microorganisms and endogenous
biomarkers of sepsis, impacting the 14 000 annual deaths in the
UK due to sepsis could have been prevented by earlier diagnosis
and intervention.90
3. Proposed development pathway
Health care systems, including in the UK, are under consider-
able strain, with ever increasing resource demands to treat
more patients with the highest quality of care while minimizing
costs. On average, a patient is checked every 4 h for signs of
sepsis and infection in ICUs in UK hospitals, during which time
a patient's condition can deteriorate to become life-threat-
ening.91 Rapid testing has potential to inform clinical care,
including escalation or change of therapy. It is evident that
accurate and reliable analysis of small blood samples at point-
of-care would represent a pivotal development. The tech-
nology would also be useful in creating a baseline at time of
presentation to monitor progress or deterioration, especially it
if can t seamlessly into the clinical workow.
We propose specically for the diagnosis of sepsis the
development of a point-of-care device that is capable of rapid
blood analysis using vibrational spectroscopy by providing
critical data on differential white blood cell counts and key
infection biomarkers. This approach for the early identication
of sepsis would complement clinical judgment to provide
a more thorough diagnostic approach. There is also scope for
this technology to be adapted for spectral identication of
microbes, and for detection of antimicrobial resistance to
guiding antibiotic therapy. At present, UK metropolitan hospi-
tals aim to provide full blood counts from patients in emergency
within a minimum time of 40 min from receipt of the sample in
the lab but in reality this oen takes over an hour.92 A novel
point-of-care diagnostic tool must be then capable of producing
a result in much less time, which is a signicant technical
challenge. However, if the technology barriers can be overcome,
then there are multiple additional clinical applications. One
example is routine blood analysis within healthcare centres and
family practices. Since an appointment with a family doctor
lasts typically about 10min, this represents a target turn-around
time for the diagnostic test, avoiding the need to send samples
to a diagnostic laboratory, thereby easing the burden on
hospital labs that could then give priority to the most critical-ill
patients. There is also scope for such a device to be used in
remote and rural clinics, eld hospitals and in low-resource
settings. Additionally, its use by paramedical and rst-
responder personnel could allow patients to be agged before
reaching the emergency department, so as to allow immediate
treatment and stabilisation.
4. Conclusions
The application of vibrational spectroscopy in the quest of early
disease diagnostics has been a major focus in recent years, due
to its rapid and non-invasive nature and cost-effectiveness.
Although currently not fully translated into the clinical envi-
ronment, there is signicance for early diagnostics, patientThis journal is © The Royal Society of Chemistry 2021






























































































View Article Onlinemonitoring, and treatment guidance. This review has high-
lighted the potential for point-of-care spectroscopic devices for
blood the analysis in particular, to aid in the diagnosis of
infections and sepsis by providing a rapid and accurate tool to
quantify sepsis-related biomarkers and to detect/identify the
causative pathogens. The current diagnostic pathway involves
numerous steps for identication of infections and sepsis, and
uses technologies requiring extensive sample preparation and
analysis time. It has been well recognized that these current
methods are inadequate and cause signicant delays in diag-
nosis and initiation of effective treatment, that negatively
impacts the staggering number of hospitalisations and deaths
worldwide each year (30 and 9 million, respectively32). Earlier
diagnosis of sepsis would save more than 14 000 lives annually
and reduce healthcare costs by upwards of £170 million in the
UK alone.3,90 Vibrational spectroscopy can, in principle and
likely also in practice, overcome these limitations by providing
a rapid, label-free analytical tool for point-of-care blood anal-
ysis, and is the focus of ongoing research and development.
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